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Numerous studies have demonstrated a correlation
between hyaluronan expression and the malignant
properties of various kinds of cancer, and inhibition
of hyaluronan production causes decreased tumor
growth. Hyaluronan oligosaccharides have been
shown to inhibit several tumor cell types via disrup-
tion of receptor-hyaluronan interaction. However,
few studies have addressed hyaluronan with respect
to osteosarcoma. In this study, we examined the ef-
fects of exogenously added hyaluronan oligosaccha-
rides on tumorigenicity of murine osteosarcoma
cells, LM-8, and human osteoblastic osteosarcoma
cells, MG-63. Moreover, the critical size of oligomers
needed to inhibit malignant properties was defined.
Fluorescent hyaluronan oligosaccharides accumu-
lated both on the surface of cells and in the cyto-
plasm, and this retention was blocked by pretreat-
ment with an anti-CD44 monoclonal antibody.
Hyaluronan octasaccharides significantly inhibited
cell viability and induced apoptosis as defined by cell
proliferation and terminal deoxynucleotidyl trans-
ferase dUTP nick-end labeling assays, respectively.
Octasaccharides also abrogated functional cell-associ-
ated matrices and significantly reduced the retention
of endogenous hyaluronan. Further, octasaccharide
treatment affected an inhibition of cell motility as
well as cell invasiveness. Pretreatment of the cells
with anti-CD44 antibody reduced the antitumor effect
of the octasaccharides. In vivo , intratumoral injection
of hyaluronan octasaccharides reduced the hyaluronan
accumulation in local tumors, resulting in significant
suppression of the formation of distant lungmetastasis.
Together these data suggest that hyaluronan oligosac-
charides have potent antitumor effects functioning in
part by the abrogation of hyaluronan-rich cell-associ-
ated matrices. (Am J Pathol 2007, 171:274–286; DOI:
10.2353/ajpath.2007.060828)
Hyaluronan (HA) is a high-molecular-weight linear gly-
cosaminoglycan comprised of repeating disaccharide
units, glucuronic acid, and N-acetylglucosamine. HA is
an abundant component of the extracellular matrix and
plays a role in regulating matrix assembly, cell migration,
differentiation, and proliferation.1–3 HA expression in-
creases during active tissue remodeling, eg, during mor-
phogenesis and wound healing.4 Furthermore, HA bind-
ing proteins also contribute to these cellular behaviors
through interactions with HA and assembly of pericellular
coats.5 Increased HA levels are also observed in malig-
nant tumors, including gastric cancer, colorectal cancer,
breast cancer, glioma, lung cancer, and ovarian can-
cer.6–14 In vitro studies have demonstrated that the HA
levels correlate with the invasive and metastatic capacity
of tumor cells.15,16 Increased HA-rich matrix deposition
may help invasion by providing a suitable environment for
cancer cells,6 stimulating cell motility via interactions with
cell surface receptors of HA,17 and forming a barrier for
cancer cells against host immunocompetent cells.18 Per-
turbations of these endogenous HA-HA receptor interac-
tions often inhibit tumor growth, invasion, or metastasis in
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select kinds of cancer.19–24 HA oligosaccharides also
have inhibitory effects on tumor growth25 via competing
for endogenous polymeric HA, replacing high-affinity,
multivalent receptor interactions with low-affinity, low-va-
lency interactions.26,27
Osteosarcoma is the most frequent primary malignant
bone tumor in children and adolescents.28,29 The term
osteosarcoma is used to describe a heterogeneous
group of lesions with diverse morphology and clinical
behavior. Understanding the basic biology of heteroge-
neous osteosarcoma may provide insight for a novel tool
for treatment. The prognosis of osteosarcoma has been
improved with the introduction of chemotherapy; how-
ever, it is difficult to improve current response rates even
with progressive dose escalation. Therefore, there is a
clear need to develop newer and alternative agents for
the treatment of patients with osteosarcoma.
Little has been reported on the association of HA and
osteosarcoma tumorigenicity. The selective inhibition of
HA synthase-2 (HAS-2) mRNA in osteoblastic osteosar-
coma cells, MG-63, by antisense phosphorothioate oligo-
nucleotides reduces HA accumulation and diminishes
cell-associated matrix formation by these cells. These
changes subsequently affect a substantial decrease in
cell proliferation, a decrease in cell motility, and a de-
crease in cell invasiveness.30 MG-63 cells also have an
abundant HA-rich cell-associated matrix, leading to the
hypothesis that inhibition of this HA-rich matrix retention
at the cell surface might have effects on the tumorigenic-
ity of these cells as well. However, the use of HAS-2
antisense oligonucleotides to inhibit HA synthesis has
limited clinical practicality at present. Recently, investi-
gators have used small oligosaccharides of HA to de-
plete HA-rich matrices from cells.31,32 The proposed
mechanism is that these small oligosaccharides compete
with the binding of high-molecular-mass HA with cell
surface receptors such as CD44. Given their size, purity,
and ease of permeability into tissues, the use of such
small oligosaccharides may have suitable clinical
applicability.
In this study, we determined the critical size of HA
oligosaccharides necessary to inhibit cell surface reten-
tion of HA in the osteoblastic osteosarcoma cell line
MG-63 and to provide for antitumor effects. In addition,
the effects of HA oligosaccharide application to osteo-
sarcoma tumors in vivo were analyzed.
Materials and Methods
Reagents
Dulbecco’s modified Eagle’s medium (DMEM), trypsin
ethylenediamine tetraacetic acid, and TRIzol reagent
for RNA isolation were obtained from Gibco BRL
(Grand Island, NY). Fetal bovine serum was purchased
from Hyclone (Logan, UT). High-molecular-weight hya-
luronan (HMWHA; 600 to 1200 kd) was purchased from
Seikagaku Co. (Tokyo, Japan). Anti-CD44 monoclonal
antibodies, Hermes-1, homing-associated cell adhe-
sion molecule (HCAM), and IM7 were purchased from
Pierce Biotechnology, Inc. (Rockford, IL), BioVision Re-
search Products (Mountain View, CA), and StemCell
Technologies (Seattle, WA), respectively. A GeneAmp
RNA PCR kit for reverse transcription-polymerase
chain reaction was purchased from Perkin-Elmer (Nor-
walk, CT). Specific primers for HAS-1, HAS-2, HAS-3,
CD44, and glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) were custom made by Integrated DNA
Technologies (Coralville, IA). SYBR Green I gel stain
was purchased from Molecular Probes (Eugene, OR).
Biotinylated hyaluronic acid binding protein was pur-
chased from Seikagaku America (Falmouth, MA). Hu-
man sCD44std enzyme-linked immunosorbent assay
(ELISA) kit was purchased from Bender MedSystems
(Vienna, Austria). Streptavidin peroxidase (component
of the Vectastain ABC kit) was purchased from Vector
Laboratories (Burlingame, CA). Agarose was from FMC
BioProducts (Rockland, ME). Cell Proliferation Kit I was
purchased from Roche (Mannheim, Germany). Trans-
well inserts with 12.0-!m pore size were purchased
from Corning Inc. (Corning, NY). Matrigel was pur-
chased from BD Biosciences (Bedford, MA). All other
enzymes and chemicals, molecular biology grade or
reagent grade materials, and CelLytic-M were pur-
chased from Sigma Chemical Co. (St. Louis, MO).
Cell Culture
MG-63 cells (human osteoblastic osteosarcoma cell line)
from the American Type Culture Collection (Manassas,
VA) and LM-8 (murine osteosarcoma cells; a kind gift
from Dr. A. Uchida, University of Mie, Tsu, Japan) were
maintained at 37°C in an atmosphere with 5% CO2 with
DMEM, supplemented with 10% fetal bovine serum, pen-
icillin, and streptomycin. The cells were cultured in the
presence or absence of HMWHA or various-sized HA
oligosaccharides (HA oligos) in chamber slides at a con-
centration of 1 ! 104 cells/well for Fl-HA, terminal deoxy-
nucleotidyl transferase dUTP nick-end labeling (TUNEL),
and HA staining. The cells were cultured in 12-well plates
as monolayer cultures at a concentration of 1 ! 104
cells/dish for particle exclusion assay. For cell prolifera-
tion assays, the cells were cultured in 96-well plates at a
concentration of 104 cells/well and in Transwells with
12.0-!m pore size at a concentration of 5! 105 cells/well
for cell invasion or motility assays.
Hyaluronan Oligosaccharides
HA oligos and fluorescein isothiocyanate-conjugated
hyaluronan oligosaccharides (FITC-oligos) were pre-
pared by Seikagaku Co. as described previously.33 In
brief, HA was depolymerized by partial digestion with
testicular hyaluronidase and separated into size-uniform
HA oligos by anion exchange chromatography after re-
moval of the hyaluronidase. FITC-conjugated HA oligo-
saccharides of 34 monosaccharides in length (FITC-HA
oligos; 34 mers) were obtained from Seikagaku Co. The
purity and size of each HA oligo was confirmed by using
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high-performance liquid chromatography analyses. En-
dotoxins, proteins, and DNA were absent in these oligo-
saccharide preparations.
Distribution of Exogenous FITC-HA
Oligosaccharides
The retention of exogenously added FITC-HA oligos was
investigated using MG-63 and LM-8 cells cultured on
chamber slides at a density of 5.0 ! 104 cells/well for 2
hours, treated with 250 !g/ml FITC-HA oligos for 24
hours, washed three times with phosphate-buffered sa-
line (PBS), and then observed using a fluorescent micro-
scope (Olympus CKX-FL-1; Tokyo, Japan) equipped with
a digital camera (Olympus Camedia C-5050). To evalu-
ate the specific binding of FITC-HA oligos to CD44, a cell
surface receptor of HA, cells were pretreated with an
anti-CD44 neutralizing antibody, Hermes-1 (0 to 10 !g/
ml) or HCAM (0 to 10 !g/ml), for 2 hours before the
addition of FITC-HA oligos for 24 hours at 37°C. MG-63
cells were pretreated with Hermes-1, and LM-8 cells were
pretreated with the HCAM antibody. After washing three
times with PBS, the retention of the FITC-HA oligos was
evaluated by fluorescent microscopy. Fluorescence in-
tensity of cells was semiquantified with ATTO Image
Analysis software, CS Analyzer version 2.00a (ATTO
Corp., Tokyo, Japan).
Cell Viability Assay
Given that the length of FITC-HA oligos might be cru-
cial for antitumor effects, we performed a cell viability
assay with treatment of HA tetrasaccharides, hexasac-
charides, octasaccharides, decasaccharides, and do-
decasaccharides (HA4, HA6, HA8, HA10, HA12) as
well as HMWHA. Cell proliferation was measured by
the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazo-
lium bromide (MTT) colorimetric assay 48 hours after
treatment with or without 250 !g/ml HA4, HA6, HA8,
HA10, HA12, or HMWHA. Preliminary studies demon-
strated that at 48 hours, the cultures remained subcon-
fluent and generated values within the linear optimal
ranges of the MTT assay. Microscopic inspection of the
wells confirmed that decreased absorbance values
correlated with decreased cell number. Color intensity
was determined on a microculture plate reader at 550
nm. The data presented are the means " SD from
triplicate wells per microtiter plate with three replicate
microtiter plates per experiment. Based on the results
of cell proliferation assays, HA4, HA8, and HMWHA
were used for all of the following experiments. To eval-
uate whether the antitumor effects of HA8 were medi-
ated via CD44, MG-63 cells were pretreated with 10
!g/ml anti-CD44 antibodies, either Hermes-1 or IM7,
for 2 hours at 4°C, followed by HA8 for 48 hours and
then assayed for cell viability using the MTT assay.
TUNEL Staining
TUNEL staining was used to evaluate the apoptotic
effect of HA oligos on MG-63 or LM-8 cells. The cells
were seeded into chamber slides (Becton Dickinson
Labware, Franklin Lakes, NJ) and allowed to adhere to
the bottom of the slides for 12 hours. The cells were
incubated with or without 250 !g/ml HA4, HA8, or
HMWHA. After 72 hours of culture, the cells were fixed
with paraformaldehyde and evaluated by TUNEL stain-
ing using an In Situ Cell Death Detection Kit, POD
(Roche Diagnostics GmbH). The cells were counter-
stained with hematoxylin-eosin. Cells with brown-
stained nuclei in 20 different fields were counted under
a light microscope at a magnification of 400!, and the
percentage of positive-staining cells treated with HA
oligomers was compared with positive-staining cells
within the untreated control group.
Staining for HA
The cells were seeded into chamber slides (Becton Dick-
inson Labware) at a density of 104 cells/well, allowed to
adhere to the bottom of the slides for 12 hours, and then
treated with or without 250 !g/ml HA4, HA8, or HMWHA
for 72 hours. Cultured MG-63 cells were fixed with 2%
paraformaldehyde buffered with PBS at room tempera-
ture for 2 hours. The cells were treated with 0.3% H2O2 in
30% methanol for 30 minutes at room temperature to
block the internal peroxidase activity, followed by incu-
bation with 1% bovine serum albumin in PBS for 1 hour at
room temperature. Cells were then incubated with 2.0
!g/ml biotinylated HA-binding protein (b-HABP) probe
for 2 hours at room temperature. This b-HABP binds to
HA with high affinity and specificity (similar to an anti-
body) with a minimum binding site of #41 HA monosac-
charides. Bound b-HABP was detected by the addition of
streptavidin-peroxidase reagents (Vectastain kit) and
diaminobenzidine-containing substrate solution (Sigma
Fast DAB). As a control, cells were pretreated with 5
units/ml Streptomyces hyaluronidase for 1 hour at 60°C
before incubation with b-HABP.
Particle Exclusion Assay
Cell-associated pericellular matrices were visualized us-
ing a particle exclusion assay.34 Briefly, following the
72-hour treatment of monolayer cultures of MG-63 cells in
35-mm diameter dishes, with or without HA4, HA8, or
HMWHA, the culture medium was removed and replaced
with a 0.75-ml suspension of formalin-fixed erythrocytes
(108 per ml) in PBS containing 0.1% bovine serum albu-
min. The particles were allowed to settle for 15 minutes.
The cells were observed and photographed with an in-
verted phase-contrast microscope. Morphometric analy-
sis for b-HABP stainable areas and functional cell-asso-
ciated matrix areas of randomly selected cells captured
as digital images were analyzed using NIH Image soft-
ware (Bethesda, MD). A matrix area was defined by the
area delineated by the cell-associated matrix minus the
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area delineated by the plasma membrane (defined as
cell area). In the absence of detectable matrix, the matrix/
cell ratio would be 0.0.
Reverse Transcriptase-Polymerase Chain
Reaction (RT-PCR)
Total RNA was isolated from MG-63 cells that had been
treated with or without 250 !g/ml HA4, HA8, or HM-
WHA for 7 days. The cells were treated with TRIzol (Life
Technologies, Grand Island, NY) following the manu-
facturer’s instructions. The purified RNA was dissolved
in diethyl pyrocarbonate-treated H2O, and the concen-
tration of RNA in the samples was measured by its
absorbance at 260 nm. In some experiments, total
cytoplasmic RNA extracted from MG-63 cells with
TRIzol reagents was subjected to reverse transcription
and quantitative competitive PCR. Briefly, 0.125 !g of
total RNA was converted to cDNA using Moloney mu-
rine leukemia virus reverse transcriptase in the pres-
ence of 0.15 !mol/L HAS-2- or CD44-specific down-
stream primers (HAS-2: 5$-TTTCTTTATGTGACTCATC-
TGTCTCACCGG-3$; CD44: 5$-AACCGCGAGAATCAA-
AGCCAAGGCC-3$). DNA fragments that share the
same primer template sequence with the target cDNA
but contain a completely different, smaller or larger
intervening sequence, were prepared and used as
DNA internal standards (ie, mimics).35–37 Aliquots of
sample cDNA mixed together with serial dilutions of
DNA mimics were coamplified as templates in the
presence of downstream primers and 0.15 !mol/L up-
stream primers for HAS-2 and CD44 (HAS-2 upstream:
5$-ATTGTTGGCTACCAGTTTATCCAAACGG-3$; CD44
upstream: 5$-GATCCACCCCAATTCCATCTGTAC-3$)
in a PCR mixture consisting of 2 mmol/L magnesium
chloride, 200 !mol/L of each deoxyribonucleotide, and
2.5 units of AmpliTaq DNA polymerase. The DNA was
denatured by heating at 95°C for 2 minutes, followed
by 23 cycles of 1 minute at 95°C, annealing at 60°C,
and extension at 72°C for 1 minute (Perkin-Elmer
thermocycler). This reaction was followed by a final
elongation step that lasted 5 minutes at 72°C. The
amplified products were analyzed by electrophoresis
on 1.5% agarose gels followed by staining with SYBR
Green I. The stained products were scanned and
quantified using a fluoroimaging system (Molecular
Dynamics, Sunnyvale, CA).
In other experiments, HAS-1 and HAS-3 expression
was determined using conventional RT-PCR analysis.
Following reverse transcription of total RNA into cDNA as
above, the samples were PCR-amplified for 35 cycles in
the presence of 0.15 !mol/L HAS-1 and -3 specific prim-
ers (HAS-1 upstream: 5$-GGACTACGTGCAGGTCTGTG-
ACTC-3$; downstream: 5$-ACTTGGTAGCATAACCCAT-
GCTGAG-3$; HAS-3 upstream: 5$-AGAGACCCCCACTA-
AGTACCTCCG-3$; downstream: 5$-CAGAAGGCTGGA-
CATATAGAGGAGGG-3$) as well as GAPDH primer
pairs. As a positive control for HAS-1 mRNA expression,
total RNA isolated from human synovial cells was used.
To determine that all samples contained equivalent
amounts of RNA (or to normalize results due to small
differences), in a separate set of reactions total RNA from
samples were coamplified in the presence of serial dilu-
tions of an RNA internal standard (mimic) prepared for
GAPDH. The GAPDH RNA mimic shares the same primer
template sequence but contains a smaller intervening
sequence. Samples containing 0.125 !g of sample total
RNA were co-reverse-transcribed with twofold serial
dilutions of GAPDH RNA mimic in the presence of
0.15 !mol/L GAPDH-specific downstream primer (5$-
TTACTCCTTGGAGGCCATGTGGGCC-3$). The sample
and mimic cDNA products were then co-amplified in the
presence of the GAPDH-specific downstream primer to-
gether with 0.15 !mol/L upstream primer (5$-ACTGC-
CACCCAGAAGACTGTGGATGG-3$) using PCR condi-
tions as described for HAS-2 amplification.
ELISA Analysis for Protein Expression of CD44
Changes in CD44 protein expression in MG-63 cells with
or without exposure to HA4, HA8, or HMWHA for 7 days
were quantified using a human sCD44std ELISA kit. Cell
proteins were extracted using CelLytic-M according to
the manufacturer’s instructions. Concentration of the re-
agent including extracted protein of each sample was
measured by bicinchoninic acid protein assay. One hun-
dred microliters (1.6 mg/ml) of each sample was sub-
jected to the ELISA analysis. Color intensity was quanti-
fied on a microtiter plate reader at 450 nm. The data
presented are the means " SD from triplicate wells per
treatment.
Motility and Matrigel Invasion Assays
Chemotactic motility of MG-63 cells was investigated
using 12-well cell culture chambers containing inserts
with 12-!m pores. Invasion of MG-63 or LM-8 cells was
assayed in the same chambers that also contained a
reconstituted extracellular matrix supported on the
membrane (Matrigel layered on a 12-!m pore mem-
brane). Cells were added to the upper chamber (5 !
105 cells/500 !l of DMEM/well) in the presence or
absence of HA4, HA8, and HMWHA, and 1500 !l of
chemotaxis buffer including 10 !g/ml fibronectin was
placed in the lower chamber. After incubation for 24
hours at 37°C and 5% CO2, cells on the upper surface
were wiped off with a cotton swab. Migrating and in-
vading cells on the lower surface of the membrane
were stained with hematoxylin. Cells from 20 different
fields were counted under the light microscope using a
magnification of !200.
Effects of Hyaluronan Oligosaccharides on
Tumor Growth and Lung Metastasis in Vivo
LM-8 cells were used in this study, since they are known
to be tumorigenic when injected subcutaneously into syn-
geneic hosts, consistently forming local tumor masses as
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well as distant lung metastases.38 LM-8 cells (2 ! 106)
suspended in 200 !l of serum-free DMEM were im-
planted into the dorsal flank of 5-week-old C3H/He mice
and allowed to grow in vivo for a period of 14 days, at
which time small tumors were identified. The mice were
randomly divided into four groups (n % 5 mice/group), a
control group and groups treated with HA4, HA8, or
HMWHA at a concentration of 250 !g/ml. One hundred
microliters of DMEM containing HA oligos or HMWHA
were injected daily directly into the primary tumor mass
from day 14 to day 23. The same volume of DMEM was
injected into the control mice. At day 28, all of the mice
were sacrificed and their local tumors and lungs excised
and subjected to the analysis for tumor wet weight and
the number of metastatic colonies to the lung, respec-
tively. The excised lungs were fixed in 5% buffered for-
malin and stained with hematoxylin. The number of met-
astatic lesions in the lungs was counted under a
microscope at the coronal-midline section.
Effects of HA Oligosaccharides on HA and
CD44 Expression in Local Tumors
Primary local tumors were established in the dorsal flank
of the mice and allowed to grow for 14 days. The subcu-
taneous tumors were then treated without or with daily
single injections of 250 !g/ml HA oligomers for 10 days.
The tumors were then excised, fixed with 10% formalin,
and embedded in paraffin. Sections of 6 !m were sub-
jected to HA histochemistry using b-HABP and CD44
immunohistochemistry using the anti-CD44 monoclonal
antibody HCAM.
Statistical Analysis
All of the quantitative experiments were performed more
than three times. Data were statistically analyzed using
analysis of variance and the post hoc test (Bonferroni-
Dunn). P values of less than 0.05 were considered sta-
tistically significant.
Results
Retention and Localization of Exogenous
FITC-Conjugated HA Oligos
Because the smaller-sized HA oligos such as HA4 and
HA8 could not be conjugated with FITC, 34-mers of HA
oligos were conjugated with FITC and used in a cellular
localization assay. As shown in Figure 1, A and D, FITC-
conjugated HA 34-mers accumulated at the cell surface
and in the cytoplasm of MG-63 and LM-8 cells, respec-
tively. The cell surface retention of HA oligos was specif-
ically blocked in a dose-dependent manner using neu-
tralizing anti-CD44 monoclonal antibodies, Hermes-1 for
MG-63 and HCAM for LM-8 cells (Figure 1, B and C, and
E and F, respectively), suggesting the binding of HA
oligos to the cell surface was mediated by CD44. The
relative fluorescence intensities of representative MG-63
cells, determined by ATTO Image Analysis software,
were 101.0, 35.6, and 18.1 following pretreatment of 0, 5,
and 10 !g/ml Hermes-1. Changes in the relative fluores-
cence intensity of representative LM-8 cells were 132,
52.2, and 32.2 following pretreatment of 0, 5, and 10
!g/ml HCAM, respectively.
Cell Viability Assay
The effect of various sizes of HA oligos on cell viability
was examined. Previous studies on chondrocytes had
demonstrated that an effective concentration of 250
!g/ml of exogenous HA oligos was necessary to affect
cell behavior.31 As shown in Figure 2A, both HA oligos as
Figure 1. Retention of FITC-HA oligos is medi-
ated by CD44. MG-63 cells at a density of 5.0 !
104 cells/well were pretreated with 0, 5, or
10 !g/ml anti-CD44 monoclonal antibody
(Hermes-1) for 2 hours at 4°C (A–C, respec-
tively). LM-8 cells at the same density were also
pretreated with 0, 5, and 10 !g/ml anti-CD44
monoclonal antibody (HCAM) for 2 hours at 4°C
(D–F, respectively). After washes, the cells were
next incubated with 250 !g/ml FITC-conjugated
HA oligos for 24 hours at 37°C. After washing
with PBS three times, the cultures were exam-
ined by fluorescent microscopy and imaged us-
ing a digital camera (Olympus Camedia C-5050)
(original magnification, !400). Fluorescence of
the representative single cell was semiquantified
with ATTO Image Analysis software, CS Analyzer
version 2.00a.
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well as HMWHA inhibited the growth of the MG-63 cells at
this concentration. The HA10 and HA12 oligos exhibited
the greatest effect of 40% inhibition following 48 hours of
treatment (P & 0.0001 and P & 0.0001, respectively,
compared with control), followed in activity by a 35%
reduction following treatment with the HA8 oligos (P &
0.0001). Less inhibition was observed following treatment
of the cells with HA4, HA6, or HWMHA (P % 0.1044, P %
0.001, and P & 0.0001, respectively). HA8 also inhibited
the growth of the LM-8 cells significantly (P& 0.0001). To
maximize differences between groups, all subsequent
experiments were performed with HA4, HA8, and HM-
WHA for comparison.
To evaluate whether the antigrowth effects of HA8 were
mediated via CD44, the MG-63 cells were pretreated
with the blocking anti-CD44 antibodies, either IM7 or
Hermes-1. As shown in Figure 2C, compared with control
cells, the HA8 exhibited potent antiproliferative activity
(63% decrease, P & 0.05). Pretreatment with IM-7 or
Hermes-1 also resulted in a modest 30 to 35% decrease
in cell number. However, pretreatment with either IM-7 or
Hermes-1 before HA8 addition reduced the antiprolifera-
tive effects of HA8 (Figure 2C) back to levels observed
with IM-7 or Hermes-1 alone. These data suggest that the
cellular effects of HA8 are mediated through interactions
with CD44.
Effects of HA Oligos on Apoptotic Activity
To determine the mechanism of the growth inhibitory
effects of HA oligos on MG-63 and LM-8 cells, the num-
ber of apoptotic cells was determined by TUNEL staining.
As shown in Figure 3A, the average percentage (mean "
SD) of apoptotic MG-63 cells’ exposure to HA8 was sig-
nificantly increased (2.2-fold stimulatory effect) as com-
pared with the control (P & 0.0001), whereas there was
no significant increase in apoptotic activity observed on
exposure to HA4 or HMWHA (P % 01415 and P % 03321,
respectively). Apoptotic activity was also significantly
stimulated in LM-8 cells (1.5-fold) following treatment with
HA8 (P & 0.0001, Figure 3B).
Effects of HA Oligos on Functional
Cell-Associated Matrix of MG-63 Cells
Biotinylated HABP (b-HABP) was used to visualize en-
dogenous HMWHA retained at the cell surface of MG-63
cells. As shown in Figure 4D, control MG-63 cells exhib-
ited prominent b-HABP staining (arrows) indicative of
HA-rich cell-associated matrix. Because the cells were
permeabilized in the preparation, intracellular granules
containing HA could also be detected (Figure 4D, arrow-
heads). Differences in b-HABP-stainable areas were de-
termined by morphometric analysis (Figure 4E). Treat-
ment of cells with HA4 (Figure 4A) or HMWHA (Figure 4C)
did not result in significant changes in b-HABP staining
as compared with control culture (P % 0.89 and P %
0.152, respectively). However, cells treated with HA8
Figure 2. Effect of HA oligos on MG-63 and LM-8 cell viability. MG-63 (A)
and LM-8 (B) cells were treated with various HA oligos or HMWHA for 48
hours and then assayed for cell viability using a MTT assay. MG-63 cells were
pretreated with 10 !g/ml anti-CD44 monoclonal antibodies (IM-7 or
Hermes-1) for 2 hours at 4°C, incubated with or without HA8 for 48 hours,
and then assayed for cell viability using a MTT assay. Values represent the
average " SD compared with control absorbance (control % 1.0) derived
from experiments performed in triplicate (C). Values represent the average"
SD of absorbance readings at 550 nm derived from experiments performed in
triplicate (**P & 0.01).
Figure 3. Effects of HA oligos on apoptotic activity in osteosarcoma cells.
MG-63 (A) and LM-8 (B) cells in monolayer were cultured with or without
250 !g/ml HA4, HA8, HMWHA for 72 hours and then analyzed by TUNEL
staining using an In Situ Cell Death Detection Kit. The percentage of positive
cells with brown-stained nuclei was calculated in 20 different fields using
light microscopy at a magnification of !400. Percentage of apoptotic cells
with treatment of HMWHA or HA oligos was compared with control (control,
1.0) and indicated as the y axis. Bars represent means " SD. **Statistically
significant difference from control group (P & 0.01).
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displayed a 64% decrease in staining for HA within cell-
associated matrix (Figure 4B) compared with control
(P & 00001). Thus, only the HA8 oligosaccharides af-
fected the retention of endogenous HMWHA to MG-63
cells.
One of the functions of surface-retained HA is to
serve as a scaffold for the assembly of a cell-associ-
ated matrix.5,34,39 On tumor cells, such matrices may
favor tumor growth and survival by inhibiting apoptosis
or shielding the tumor cells from immunocompetent
cells.18 Cell-associated matrices can be visualized
around live MG-63 cells by use of a particle exclusion
assay (Figure 5D). These cell-associated matrices
could be abrogated by treating tumor cells with HA8
(Figure 5B). Morphometric analysis indicated the 70%
decrease in functional cell-associated matrix with
treatment of HA8 as compared with control (Figure 5I,
P & 0.0001). HMWHA treatment (Figure 5C) also re-
sulted in a substantial decrease in the diameter of
cell-associated matrices (Figure 5I, P % 0.041), al-
though the effect of HA8 was more prominent. Similar
inhibitory effects of HA8 were observed on LM-8 cells.
HA8 treatment resulted in a statistically significant 50%
decrease of functional cell-associated matrix (Figure
5F) compared with control (Figure 5H, P & 0.0001).
Changes in HAS and CD44 mRNA Levels after
the Treatment of HA Oligos
HAS-2 has been demonstrated to be a main enzyme
involved in the synthesis of HA by MG-63 cells.30 Fur-
thermore, the results of FITC-HA 34-mers binding (Fig-
ure 1) and displacement of endogenous HA by HA8
(Figure 4B) suggest that CD44 is the principal cell-
surface receptor of HA in MG-63 cells. To determine
whether HA oligos affect the expression of either
HAS-2 or CD44 mRNA in MG-63 cells, the cells treated
with HA oligos were analyzed by quantitative compet-
itive RT-PCR (Figure 6, A and B). HAS-2 mRNA copy
number was normalized by GAPDH copy numbers. As
shown in Figure 6C, treatment of MG-63 cells with HA8
resulted in a 19% up-regulation of HAS-2 mRNA ex-
pression after 7 days after treatment, compared with
the control (P % 0.1488). No significant effects on
HAS-2 were observed following treatment with HA4
oligos or HMWHA (Figure 6C). There was 139% in-
crease of CD44 mRNA levels following treatment of the
cells with HA8 compared with control (Figure 6D, P %
0.0009). HA4 oligos also affected an increase in CD44,
but the increase was not as prominent as following HA8
treatment. HMWHA had no effect on CD44 expression
(Figure 5D). Stimulated expression of CD44 mRNA fol-
lowing treatment with HA8 (Figure 6D) was consistent
with the CD44 protein expression determined by ELISA
analysis; CD44 in HA8-treated cells was significantly
higher compared with control (Figure 6G, P % 0.0004).
To clarify whether compensatory expression of other
HAS isoforms had occurred, primer sets for HAS-1 and
HAS-3 were tested using conventional RT-PCR amplifi-
cation. As shown in Figure 6F, the expression of HAS-3
mRNA was also up-regulated with treatment of HA8 com-
pared with control, but no changes in GAPDH mRNA
were detected (Figure 6E). Although HAS-1 mRNA was
detected using total RNA isolated from the synovia of
Figure 4. Effect of HA oligos on HA retention in
MG-63 cells. MG-63 cells were treated with 250
!g/ml HA4 (A), HA8 (B), HMWHA (C), or control
medium (D) for 72 hours, fixed in 2% paraformal-
dehyde, and then stained for HA using a biotinyl-
ated HABP reagent. All cells were photographed
and printed at the same magnification (original
magnification, !200). Arrows and arrowheads
are defined under Effects of HA Oligos on Func-
tional Cell-Associated Matrix of MG-63 Cells. Mor-
phometric analyses were used to determine ratios
of the area delineated by the cell-associated matrix
to the area delineated by the plasma membrane
(HABP staining; E). Bars represent means " SD
from 20 cells of each treatment (**P & 0.0001).
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patients with rheumatoid arthritis, HAS-1 mRNA could not
be detected in any of the samples derived from MG-63
cells (data not shown).
Effect of HA Oligos on Cell Migration and
Invasiveness
As shown in Figure 7A, HA8-treated MG-63 cells exhib-
ited a statistically significant reduction (50%) in migratory
activity at the 24-hour time point compared with control
cells (P& 0.0001). In the invasion assay, the HA8-treated
MG-63 cells also exhibited a significantly lower capacity
(30%) to pass through the Matrigel-coated filters as com-
pared with control cells (Figure 7B, P & 0.0001). A slight
inhibition (30%) was observed in cells treated with
HMWHA but no change in cells treated with HA4. Inva-
siveness was also inhibited by 41% in LM-8 cells with
treatment of HA8 compared with control (Figure 7C, P &
0.0001). No significant inhibitory effects were exhibited
following treatment with HA4 or HMWHA.
Effects of HA Oligos on LM-8 Growth in Vivo
and Lung Metastasis
LM-8 cells are highly metastatic in mice and thus useful
for in vivo investigations into the efficacy of HA oligos on
tumor growth and metastasis. Like the MG-63 cells, the
LM-8 cells have abundant cell-associated matrix and
display similar sensitivity to HA oligos with regards to cell
viability, invasiveness, and apoptosis in vitro (Figures 2, 3,
and 7). In vivo, daily application of HA8 showed a trend
toward inhibition of LM-8 tumor growth (Figure 8E) as
measured by tumor mass. However, given the deviation
between tumors, the values did not reach significance.
On the other hand, treatment of the primary tumor with
HA8 did result in a significant 82% reduction in the num-
ber of metastatic lung lesions (P % 0.0136, Figure 8F).
These results can be compared visually, for example, the
lung metastasis in HA8-treated tumors (Figure 8B, ar-
rows) versus control, untreated tumor-bearing animals
(Figure 8D) or animals treated with HA4 or HMWHA (Fig-
ure 8, A and C, respectively). No additional complications
of HA oligo treatment on skin or body weight were
observed.
Effects of HA Oligos on CD44 and Hyaluronan
Expression in LM-8 Local Tumors
The inhibitory effects of HA8 treatment on lung metas-
tasis formation might be due to the abrogation of HA
retention by tumor cell CD44. Analysis for HA by b-
HABP staining and CD44 expression by immunohisto-
chemistry revealed that HA8 reduced the HA retention
in LM-8 local tumors (Figure 9B) compared with control
Figure 5. Effect of HA oligos on assembly of cell-associated matrices in
MG-63 and LM-8 cells. To visualize pericellular matrices, inert particles
(glutaraldehyde-fixed erythrocytes) were applied to cultures of MG-63 cells
following 72 hours of treatment with 250 !g/ml HA4 (A), HA8 (B), HMWHA
(C), or control medium (D), as well as LM-8 cells incubated with HA4 (E),
HA8 (F), HMWHA (G), or control medium (H). All cells were photographed
and printed at the same magnification (original magnification, !200). Mor-
phometric analyses were used to determine ratios of the area delineated by
the cell-associated matrix to the area delineated by the plasma membrane (I,
MG-63; J, LM-8). Bars represent means " SD from 10 cells of each condition
(**P & 0.0001).
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(Figure 9D), whereas the same treatment up-regulated
CD44 expression in local tumors (Figure 9F) compared
with control (Figure 9H).
Discussion
Previous studies have shown that HA plays a crucial role
in the progression of several cancers.40 Inhibition of en-
dogenous HA-tumor cell interaction results in the sup-
pression of growth and metastasis of the tumor cells.40
Reduction of anchorage-independent growth by this in-
hibition is due to suppression of the phosphoinositide
3-kinase/Akt pathway.40,41 In several types of tumor cells,
glioma42 and melanoma25 cells, antitumor effects have
been demonstrated with treatment of HA oligos. How-
ever, these studies did not analyze the effects of HA
oligosaccharides on the formation of cell-associated ma-
trix or the critical size of HA oligomers to have antitumor
effects. In this study, we showed that treatment of MG-63
human osteoblastic osteosarcoma cells, which have
abundant HA-rich cell-associated matrix,30 as well as
LM-8 murine osteosarcoma cells, with HA oligos inhibited
the formation of HA-rich cell-associated matrix, resulting
in the inhibition of growth, motility, and invasiveness and
induction of apoptotic activity in vitro. Antitumor effects
were also observed in vivo.
CD44 is the primary cell surface receptor for the HA in
many cell types.26,43 Several lines of evidence were used
in this study to implicate the participation of CD44 in the
antitumor effects elicited by the HA oligos. First, anti-
CD44 blocking antibodies prevented the binding of FITC-
conjugated HA 34-mers to the cell surface (or accumu-
lation within the cytoplasm) of MG-63 and LM-8 cells.
Although such an approach can be used to demonstrate
specific binding of HA oligos to CD44, a blocking anti-
body approach is more difficult to use to verify the par-
ticipation of CD44 in HA oligo-initiated antitumor effects.
Figure 6. Effect of HA oligo treatment on HAS and CD44 expression in
MG-63 cells. Aliquots of total RNA (0.125 !g) derived from MG-63 cells
cultures treated with 250 !g/ml HA4, HA8, HMWHA, or control medium for
7 days were reverse-transcribed and PCR-amplified for 23 cycles in the
presence of human HAS-2- or CD44-specific primers. The products were
separated on 1.5% agarose gels and visualized by SYBR Green I staining. The
gels were scanned and quantified using a fluoroimaging system (Molecular
Dynamics). RT-PCR amplification of HAS-2 is shown in A, CD44 in B. Lanes
1–4 represent in each panel amplification of RNA derived from HA4 oligo-
treated cultures; lanes 5–8, HA8-treated cultures; lanes 9–12, HMWHA-
treated cultures; lanes 13–16, control untreated cultures. In A, reverse-
transcribed cDNA samples were coamplified with 30, 15, 7.5, and 3.75
attomoles of HAS-2 DNA mimic (lanes 1–4, 5–8, 9–12, and 13–16, respec-
tively). In B, reverse-transcribed cDNA samples were coamplified with 4, 2,
1, and 0.5 attomoles of CD44 DNAmimic (lanes 1–4, 5–8, 9–12, and 13–16,
respectively). HAS-2 target product size is 409 bp; mimic size is 523 bp. CD44
target size is 587 bp; mimic size is 379 bp. After normalization of competitive
RT-PCR reactions with respect to a GAPDH RNA mimic, the ratio of mRNA
copy numbers was determined. The comparative copy number of HAS-2 (C)
and CD44 (D) mRNA derived from cultures treated with HA4, HA8, HMWHA,
or untreated controls are shown. Bars represent means " SD from three
different cultures (*P & 0.001). Aliquots of total RNA derived from MG-63
cells cultures treated with 250 !g/ml HA4, HA8, HMWHA, or control medium
for 7 days were also subjected to conventional RT-PCR for 35 cycles in the
presence of human HAS-3 or GAPDH-specific primers. Total RNA derived
from synovial cells of patients with rheumatoid arthritis was used as positive
control for the HAS-1 and -3 mRNA expression. The products were separated
on 1.5% agarose gels and visualized by ethidium bromide staining. E and F
depict the amplification of GAPDH and HAS-3, respectively, with HA4 (lane
1), HA8 (lane 2), HMWHA (lane 3), or untreated controls (lane 4). A
human sCD44std ELISA kit was used to determine changes in the expression
levels of CD44 protein. MG-63 cells with treatment of HA4, HA8, HMWHA, or
control medium for 7 days were lysed using CelLytic-M and subjected to
sCD44std ELISA. Color intensity was determined on a microtiter plate reader
at 450 nm. The data presented are the means " SD from triplicate wells per
treatment (**P & 0.001).
Figure 7. The effect of HA oligos on MG-63 or LM-8 cell motility and
invasiveness. MG-63 cells were assayed for changes in cell motility (A) and
invasiveness (B) in Boyden chambers in the absence or presence of HA4,
HA8, or HMWHA. LM-8 cells were also subjected to the assay for invasiveness
(C). Following 24 hours of incubation, the cells were fixed with 2% parafor-
maldehyde and visualized by hematoxylin staining. The number of cells on
lower surface of the membrane was counted in 20 randomly selected high-
power fields. The data are presented as the average" SD for cell motility (A)
and cell invasion (B and C). **Statistically significant difference from control
group (P & 0.0001).
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CD44-blocking antibodies, like the HA oligos, also inter-
fere with HMWHA binding to the cell surface and thus
initiate the same antitumor effects.44–46 For example, the
invasion of metastatic colon carcinoma cells into Matrigel
was inhibited by 95% following preincubation with the
anti-CD44 antibody IM7.44 In this study, both IM7 and
Hermes-1 antibodies also independently affected the
proliferation of osteosarcoma cells by 30 to 35%. How-
ever, by pretreatment with these anti-CD44 antibodies,
the antiproliferative activity the effects of HA8 (63% re-
duction in cell proliferation) were nullified.
The third line of evidence implicating CD44 in our
study is ligand size specificity. HA tetrasaccharides
(HA4) do not compete with HA binding to CD44.47,48
Lesley et al27 found that only HA oligos between 6 and 18
monosaccharides exhibited monovalent binding to
CD44. In this study we demonstrate that, although HA8
oligos have potent antitumor effects, HA4 oligos exhibit
no stimulatory effect on apoptosis or inhibitory effects on
cellular retention of HA, HAS-2 mRNA expression, migra-
tory activity, or lung metastasis. Thus, the absence or
presence of antitumor responses because of HA4 or HA8
is consistent with the ligand size specificity of CD44.
Nonetheless, although it remains possible that HA oligos
interact or interfere with another glycan-binding protein,
the data are again consistent with mediation via CD44.
That the mechanism for the antitumor responses in-
volves the displacement of HMWHA is derived from our
previous study that suppression of cell-associated matrix
in MG-63 cells by antisense oligonucleotide inhibition of
HAS-2 gene expression results in the inhibition of cell
proliferation, motility, and invasiveness.30 Indeed, MG-63
cells in logarithmic phase of proliferation show prominent
b-HABP-positive staining in the cytoplasm for HA.30 In-
terestingly, cells in control culture show dark b-HABP-
positive staining in cytoplasm, whereas cells incubated
with HA8 show light staining, suggesting that treatment of
HA8 inhibits the endogenous HA deposition in cell-asso-
ciated matrix together with the suppression of internaliza-
tion of endogenous extracellular HA through the cell sur-
face receptor CD44.49
A limitation of this study is the lack of analysis of
potential signaling pathways. Several cell surface HA
receptors including CD44 and RHAMM influence cell
proliferation, survival, and motility. Further, Toll-like re-
ceptor 4 (TLR-4) is reported to be the receptor for HA
degradation products in dendritic cells.50 Constitutive
interactions between HA and CD44 resist growth arrest
and apoptosis by cancer cells.22,41 HA has also been
demonstrated to activate the phosphatidylinositol 3 ki-
nase-AKT signaling pathway and the phosphorylation of
focal adhesion kinase and BAD.51–53 Inhibition of the
interaction between constitutive HA and CD44 reverses
these effects.41,53 In accordance with these results, our
data demonstrate that HA8, an oligosaccharide that in-
terferes with the constitutive interaction between endog-
enous HA and CD44, affects a stimulation of apoptotic
activity, whereas HA4, an oligosaccharide that does not
inhibit this interaction, does not induce apoptotic activity.
Transcriptional analysis reveals the up-regulation of
HAS-2 and CD44 mRNA levels with treatment of HA8,
which will also need further investigation to reveal the
regulatory signaling pathway. Significant increases of
HAS-2 and CD44 mRNA levels by HA8 might result from
positive feedback for reduction of cell-associated matrix
formation by osteosarcoma cells. After removal of HA8,
the cell-associated matrices of MG-63 and articular chon-
drocytes were recovered.32 Recovery of LM-8 cell matri-
ces following washout were also observed (data not
Figure 8. The effect of HA oligos on tumor mass and lung metastasis of LM-8
cells. Mouse LM8 osteosarcoma cells were transplanted subcutaneously into
C3H/He mice. From day 14 to day 23, 250 !g/ml HA4, HA8, HMWHA, or
control medium was injected daily, directly into the tumor mass. The mice
were sacrificed at day 28, the subcutaneous tumors excised, and their blotted
wet weight measured (E). In addition, numbers of lung metastases at the
coronal midline section were counted in sections of hematoxylin-stained
lung tissue (F). A to D depict representative midcoronal sections of lung
treated with HA4, HA8, HMWHA, and control, respectively. Original magni-
fication, !400. *Statistically significant difference from control group (P &
0.05).
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shown). However, direct effects of HA oligos to cell sig-
naling via some cell surface receptors remain to be
elucidated.
Antitumor effects with treatment of HA8 are more prom-
inent for lung metastasis in vivo than in vitro in the current
study. Recent studies have demonstrated that adhesion
of metastatic prostate carcinoma cells can be mediated
by the pericellular HA surrounding the metastatic cells,
whereas nonmetastatic cells having pericellular HA do
not adhere to endothelial cells.54 One explanation for the
significant reduction of the lung metastasis by osteosar-
coma cells in our studies might be due to the inhibition of
pericellular HA with treatment of locally injected HA8. The
tendency of suppression in local tumor growth may be
that abrogation of cell-associated matrix facilitates the
attack by host immunological system, together with the
direct inhibitory effects of HA8 on cell proliferation.
Although survival for patients with localized osteosar-
coma approaches 70%, the prognosis of the cases aris-
ing from pelvis or recurrent disease is dismal55,56 be-
cause of the unresectability of the tumor. Considering
that a positive margin results in the poorer prognosis for
patients, cases in which there is difficulty to obtain com-
plete tumor removal need additional chemotherapy, ra-
diotherapy, or investigational agents. Some groups have
reported using radiotherapy for unresectable patients,
but the efficacy was limited.57,58 New effective agents
against such resistant osteosarcoma should be intro-
duced, based on the understanding of the biology for
osteosarcoma.
In summary, the present study reveals the inhibitory
effects of HA oligosaccharides on cell proliferation, mo-
tility, and invasiveness in MG-63 human osteoblastic os-
teosarcoma cells as well as LM-8 murine osteosarcoma
cells via suppression of cell-associated matrix formation
and the critical length of HA for these effects. Consider-
ing that osteosarcoma is a group of heterogeneous le-
sions, size of the cell-associated matrix, expression of
cell surface receptors for HA, and signaling pathways
might diverse among cases. Accumulation of data from
various types of osteosarcoma may be necessary to shed
light on the utility of HA oligosaccharides as novel ther-
apeutic tools for uncontrollable osteosarcoma.
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